Priority Lists
Protocol Posting of
Activations
Closures
Memorandum - IMMEDIATE TEMPORARY CLOSURE TO ACCRUAL
A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
| Action Codes | NR |
| Study Coordinator(s) | Sikander Ailawadhi, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Amendments, Revisions, Memoranda
Permanent Closure - Effective 12/15/2025
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
| Action Codes | NR |
| Study Coordinator(s) | Chad Rusthoven, M.D., Paul Brown, M.D., Jeffrey Wefel, Ph.D., Abhijit Patel, M.D.,Ph.D., Justin Honce, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Revision #9 - Version Date 10/27/25
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
| Action Codes | IP, AC, RC, ER |
| Study Coordinator(s) | Vincent Chung, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum - Symptom Management and Survivorship Committee Winter Teleconference
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
| Action Codes | NR |
| Study Coordinator(s) | Norah L. Henry, M.D.,Ph.D., Dawn Hershman, M.D., M.S. |
Memorandum - Symptom Management and Survivorship Committee Winter Teleconference
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
| Action Codes | NR |
| Study Coordinator(s) | Dawn Hershman, M.D., M.S., Krishna Gunturu, M.D. |
Memorandum - Instructions for Month 24 Vital Status and Off Protocol Notice - Patient Forms
A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy
| Action Codes | NR |
| Study Coordinator(s) | Jens Rueter, M.D., Meghna Trivedi, M.D., Douglas Reding, M.D., Banu Symington, MD |
Memorandum - Symptom Management and Survivorship Committee Winter Teleconference
ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
| Action Codes | NR |
Memorandum - Important Reminder: Somatostatin Analogue Use in S2408
A Randomized Phase III Blinded Trial of lanreotide for the Prevention of Postoperative Pancreatic Fistula
| Action Codes | NR |
| Study Coordinator(s) | Robert S. Krouse, M.D., Jonathan Sham, M.D. |
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required